The estimated Net Worth of Bill Peck is at least $31.1 Миллион dollars as of 1 October 2019. Mr. Peck owns over 20,000 units of Twist Bioscience Corp stock worth over $29,425,408 and over the last 6 years he sold TWST stock worth over $1,631,671. In addition, he makes $0 as Chief Technology Officer at Twist Bioscience Corp.
Sign up
Mr. Peck TWST stock SEC Form 4 insiders trading
Bill has made over 3 trades of the Twist Bioscience Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of TWST stock worth $462,600 on 1 October 2019.
The largest trade he's ever made was selling 20,447 units of Twist Bioscience Corp stock on 3 September 2019 worth over $581,308. On average, Bill trades about 12,000 units every 6 days since 2018. As of 1 October 2019 he still owns at least 663,332 units of Twist Bioscience Corp stock.
You can see the complete history of Mr. Peck stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Bill Peck biography
Bill James Peck Ph.D. serves as Chief Technology Officer of the Company. Prior to co-founding Twist Bioscience, Dr. Peck was the Director of Fluidic Systems at Complete Genomics Inc. from April 2008 to February 2013. Dr. Peck holds a B.Sc., M.Sc., and Ph.D. in Mechanical Engineering from the University of Alberta.
How old is Bill Peck?
Bill Peck is 59, he's been the Chief Technology Officer of Twist Bioscience Corp since 2013. There are 7 older and 15 younger executives at Twist Bioscience Corp. The oldest executive at Twist Bioscience Corp is Dr. William Charles Banyai Ph.D., 66, who is the Sr. VP of Advanced Devel., GM of Data Storage & Director.
What's Bill Peck's mailing address?
Bill's mailing address filed with the SEC is C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158.
Insiders trading at Twist Bioscience Corp
Over the last 6 years, insiders at Twist Bioscience Corp have traded over $141,837,821 worth of Twist Bioscience Corp stock and bought 168,550 units worth $2,482,088 . The most active insiders traders include Fred B Craves, Keith Crandell и Emily M. Leproust. On average, Twist Bioscience Corp executives and independent directors trade stock every 8 days with the average trade being worth of $465,824. The most recent stock trade was executed by Dennis Cho on 6 September 2024, trading 275 units of TWST stock currently worth $10,769.
What does Twist Bioscience Corp do?
at twist bioscience, our expertise is synthetic dna. we have developed a proprietary semiconductor-based synthetic dna manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. by synthesizing dna on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic dna production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. the twist bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. for more information, please visit www.twistbioscience.com .
What does Twist Bioscience Corp's logo look like?
Complete history of Mr. Peck stock trades at Twist Bioscience Corp
Twist Bioscience Corp executives and stock owners
Twist Bioscience Corp executives and other stock owners filed with the SEC include:
-
Emily Leproust,
Chairman of the Board, President, Chief Executive Officer -
James Thorburn,
Chief Financial Officer -
Patrick Finn,
Chief Commercial Officer -
Dr. Emily Marine Leproust Ph.D.,
Co-Founder, Chairman, Pres & CEO -
Patrick Weiss,
Chief Operating Officer -
James M. Thorburn,
Chief Financial Officer -
Dr. Patrick John Finn Ph.D.,
Chief Commercial Officer -
Mark Daniels,
Senior Vice President, Chief Legal Officer, Chief Ethics and Compliance Officer and Secretary -
Dr. William Charles Banyai Ph.D.,
Sr. VP of Advanced Devel., GM of Data Storage & Director -
Jan Johannessen,
Independent Director -
Nelson Chan,
Independent Director -
Robert Ragusa,
Independent Director -
Keith Crandell,
Independent Director -
Robert Chess,
Lead Independent Director -
Xiaoying Mai,
Independent Director -
Nicolas Barthelemy,
Independent Director -
William Banyai,
Director -
Paula Green,
Vice President of Human Resources -
Bill Peck,
Chief Technology Officer -
Erin Smith,
Senior Vice President - Government affairs and Public policy -
Martin Kunz,
Senior Vice President - Operation -
Patrick Weiss,
Chief Operating Officer -
Tracey Mullen M.B.A.,
Sr. VP of Operations -
Paula Green,
Sr. VP of HR -
Dennis Cho,
Sr. VP, Gen. Counsel, Chief Ethics & Compliance Officer -
Kevin B. Yankton,
VP & Chief Accounting Officer -
Mark Daniels Esq.,
Sr. VP, Chief Legal Officer, Chief Ethics & Compliance Officer and Sec. -
Dr. Aaron K. Sato,
Chief Scientific Officer & Chief Scientific Officer of BioPharma -
Siyuan Chen,
Chief Technology Officer -
Adam Laponis,
Chief Financial Officer -
Alpha Fund L.P. Ever,
10% owner -
Fred B Craves,
Director -
Venture Partners Viii, Llca...,
-
Melissa A. Starovasnik,
-
Dennis Cho,
See Remarks -
Kevin Bruce Yankton,
Chief Accounting Officer -
Robert F. Werner,
Chief Accounting Officer